Form 4 for HLSQ Tessera Defense & Homeland Security Inc.
Accepted 2024-05-17 00:00:00 ET · period of report 2024-05-15 · accession 0000950170-24-061622 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-05-17 | 2024-05-15 | HLSQ | Cystic Fibrosis Foundation | 10% | X - OptEx | $0.00 | +4.78M | 9.33M | +105% | $0 |
| D | 2024-05-17 | 2024-05-15 | HLSQ | Cystic Fibrosis Foundation | 10% | X - OptEx | $0.00 | -4.78M | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock, par value $0.0001 per share | 2024-05-15 | X | A | 4,778,265 | $0.00 | 9,330,580 | D | — | — | |
| 2 | Derivative | Warrant to purchase common stock | 2024-05-15 | X | D | 4,778,265 | $0.00 | 0 | D | $0.00 · — to — | 4,778,265 Common stock | (F1) The warrant was exercisable beginning on February 27, 2023, for that number of shares that would not result in the Reporting Person beneficially owning more than 9.99% of the number of shares of common stock then issued and outstanding upon such exercise, and became exercisable in full on May 15, 2024. The warrant does not expire. |